cnbc.comSEP 173 min read$ILMN

There's a biotech stock on Josh Brown's list that's ignoring the market noise and pushing higher

Illumina (ILMN) stock has risen 160% from its October 2025 low, defying broader market trends. The genomics company reported Q2 revenue of $1.16B, up 9.5% YoY, and raised full-year guidance. The stock is up 74.5% YTD and will be added to the S&P 500. Analysts note its strong technical performance and relative strength.

Original reporting

cnbc.com

Published Sep 17, 2026, 4:45 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 17, 2026, 5:24 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

There's a biotech stock on Josh Brown's list that's ignoring the market noise and pushing higher — source image — Source · cnbc.com

Decision brief

The 30-second read

$ILMNBullishMed

Why it matters

The earnings beat and guidance raise reinforce the company's turnaround narrative, supporting a bullish outlook.

Market read

Illumina's strong earnings and guidance lift biotech sentiment and may attract momentum traders.

What to watch

Potential regulatory risk from China export restrictions could re‑emerge if geopolitical tensions rise.

Relevance 9/10Novelty 9/10Timing: today

Background

Illumina has recovered from a steep decline after a failed Grail acquisition and regulatory setbacks, now showing strong momentum.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ILMNBullishHigh confidence

Context

Illumina reported Q2 results beating consensus and raised full-year guidance, indicating stronger revenue growth and profitability.

Expected impact

Potential short-term rally with upside target near $250, support around $215.

Evidence & confidence

The beat was fresh, numbers are material, and guidance raise is sizable for a large-cap biotech.

Market effects

Sector

Illumina's outperformance may lift sentiment in the genomics and broader biotech sector.

Regional

Positive for US biotech stocks, limited impact outside the US.

Global

Highlights resilience of DNA sequencing demand globally.

Counterpoint

What could challenge this read

The stock may be overbought after a strong rally; a pullback could test $200 support.

Key entities

company
Illumina, Inc.
Genomics sequencing equipment and consumables provider.
executive
Francis deSouza
Former CEO whose resignation preceded the turnaround.

Read at source ← All news

SEP 17

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.com3 min

SEP 16

$BELow

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Vanguard S&P 500 ETF (VOO) will add Bloom Energy (BE), Illumina (ILMN), and another company, while removing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE's product revenue surged 215% due to AI demand, and ILMN raised EPS guidance. The changes have minimal impact on VOO's returns, as the fund is heavily concentrated in megacap stocks.

yahoo.com3 min

SEP 15

$ILMNHigh

Illumina Stock Climbs As Analyst Upgrades Meet S&P 500 Boost

Illumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, after UBS upgraded it to Buy with a $260 price target, and Argus raised its target to $235. The company's Q2 revenue was $1.16B, with EBITDA of $354M. Illumina is also being added to the S&P 500, effective September 21, 2026, which may drive further demand. The stock trades at a P/E ratio of 38 and P/S ratio of 6.9, reflecting its growth prospects. Analysts cite revenue reacceleration, margin expansion, and clinical demand as key driv

stockstotrade.com2 min

SEP 15

$ILMNHigh

Illumina (ILMN) Stock Draws Bullish Targets As S&P 500 Inclusion Nears

Illumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, driven by positive analyst upgrades and upcoming S&P 500 inclusion. UBS raised its target to $260, citing revenue growth and margin expansion, while Argus set a $235 target. Q2 revenue was $1.16B with strong margins. Insider selling was noted but not seen as a fundamental change.

timothysykes.com3 min

SEP 13

$BEHigh

Bloom Energy clinches S&P 500 spot alongside Illumina and Everpure

S&P Dow Jones Indices announced Bloom Energy, Illumina, and Everpure will join the S&P 500, replacing Molson Coors, The Trade Desk, and Builders FirstSource in the S&P SmallCap 600. The changes will take effect before the market opens later this quarter.

hydrogenfuelnews.com1 min

SEP 10

$ILMNHighAI 8/10

Dear Illumina Stock Fans, Mark Your Calendars for September 21

Illumina raised its full-year 2026 guidance, expecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40, citing strong clinical consumables growth and momentum in multiomics. The company also announced new leadership and partnerships. Analysts project revenue growth to $6B by 2030, with mixed stock ratings and an average price target of $207.21.

yahoo.com2 min